Accès ouvert déclaré 2026 article

Prevalence and Cure of Primary Liver Cancer in Italy by Histologic Type

Lauro Bucchi, Stefano Ferretti, Federica Toffolutti, Ugo Fedeli, Silvia Mancini, Federica Zamagni, Fabiola Giudici, Laura Botta, Manuel Zorzi, Ettore Bidoli, Francesco Cuccaro, Cinzia Gasparotti, Adele Caldarella, Mario Fusco, Monica Lanzoni, Enrica Migliore, Antonella Puppo, Maria Michiara, Rossella Cavallo, Margherita Ferrante, Giuseppe Sampietro, Walter Mazzucco, Claudia Cirilli, Rosa Vattiato, Fabrizio Stracci, Linda Guarda, Federica Manzoni, William Mantovani, Giuseppe Cascone, Caterina Palmonari, Federica Targa, Lucìa Mangone, Rocco Galasso, Antonio Porcheddu, Maria Teresa Pesce, Francesca Bella, Pietro Seghini, Anna Clara Fanetti, Pasquala Pinna, Stefano Guzzinati, Luigino Dal Maso, on behalf of the AIRTUM Working Group

0Citations signalées, ce qui n’est pas une note de qualité

32Institutions déclarées

2Pays d’affiliation déclarés

Rattachement africain : it, mv. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND/OBJECTIVES: In Italy, one- and five-year survival of primary liver cancer patients have increased in recent decades and were higher after hepatocellular carcinoma (HCC) than after intrahepatic cholangiocarcinoma (ICC). This study aimed to estimate the complete prevalence and cure indicators (long-term survival) after liver cancer diagnosis by histologic type. METHODS: Data from 31 Italian cancer registries, covering 28,057,000 residents (47% of the population), were included. The complete prevalence was calculated in 2018. The mixture-cure model was used to estimate the cure fraction (CF, proportion of newly diagnosed patients with the same life expectancy as the general population), the cure prevalence (prevalent patients who will not die as a result of cancer) and the life expectancy of fatal cases (LEF). RESULTS: In 2018, 31,723 Italians (53 per 100,000) lived after a liver cancer diagnosis. Among them, the cure prevalence was 23.3% for HCC and 40.3% for ICC. The CF remained <10% for cases diagnosed in recent decades. Higher and rising CF rates were observed between 2005 and 2015 only among patients with HCC aged <45 years (2% of all cases), with an increase from 13% to 22% in men and from 19% to 29% in women, and among patients aged 45-54 years (8% of all cases), with an increase from 7% to 15% in men and from 11% to 19% in women. The LEF for HCC in 2015 was 29 months for both sexes, an 8-month increase since 2005. CONCLUSIONS: No substantial advantage nor favourable trends in the CF was apparent for older patients with HCC as compared to those with ICC, with some progresses for the small age groups of <45 years. A clear-cut increase in CF of patients with HCC aged under 55 years occurred in the 2010s decade, with no changes for older patients. This was accompanied by an increase in the LEF. Although limited by a considerable proportion of liver cancers of unspecified histologic type, the cure indicators presented here may help monitor the long-term effects of therapeutic advances and of surveillance programmes for people with cirrhosis and HCV infection.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Prevalence and Cure of Primary Liver Cancer in Italy by Histologic Type
Date Crossref: 18/07/2026
Éditeur: MDPI AG
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori pays non établi dans la notice
Structure de recherche
University of Ferrara pays non établi dans la notice
Université ou école supérieure
Centro di Riferimento Oncologico pays non établi dans la notice
Établissement de santé
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la notice
Établissement de santé
Fondazione IRCCS Istituto Nazionale dei Tumori pays non établi dans la notice
Établissement de santé
Agenzia Regionale Sanitaria della Puglia pays non établi dans la notice
Organisme public
Regione Puglia pays non établi dans la notice
Organisme public
University of Brescia pays non établi dans la notice
Université ou école supérieure
Piedmont Reference Center for Epidemiology and Cancer Prevention pays non établi dans la notice
Établissement de santé
Regione Campania pays non établi dans la notice
Organisme public
University of Insubria pays non établi dans la notice
Université ou école supérieure
Fondazione Audiologica Varese pays non établi dans la notice
Organisation à but non lucratif

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University of Ferrara et Centro di Riferimento Oncologico, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cholangiocarcinoma and Gallbladder Cancer StudiesHepatocellular Carcinoma Treatment and PrognosisLiver Diseases and Immunity

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI